




635

11/2/03

PATENT

Attorney Docket No. 30056/30021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bennett et al.)	I hereby certify that this paper and the
)	documents referred to as enclosed
Serial No.: 09/918,186)	herewith are being deposited with the
)	United States Postal Service as First Class
Filed: July 30, 2001)	Mail, postage prepaid, in an envelope
)	addressed to Commissioner for Patents,
For: Antisense Modulation of Survivin)	P.O. Box 1450, Alexandria, Virginia
Expression)	22313 on this date:
)	
Group Art Unit: 1635)	October 24, 2003
)	
Examiner: Not Yet Assigned)	Li-Hsien Rin-Laures, M.D.
)	Registration No. 33,547
)	Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the Examiner the enclosed publications, as listed on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application. Copies of documents A1 and C1 - C4 are enclosed.

In accordance with 37 C.F.R. § 1.97(e), each item of information contained in this supplemental information disclosure statement was first cited in a European Search Report from the European Patent Office in a related European application (EP


01908740.2) less than three months prior to filing of this information disclosure statement.

No fee is required for submission of this statement because each new item of information was first cited in a counterpart European application and no item of information was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement. However, should the Patent Office determine that a fee is due for consideration of this supplemental information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,


MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:



Li-Hsien Rin-Laures, M.D.
Registration No. 33,547
Attorney for Applicants

October 24, 2003



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

30566/30021

Serial No.

09/918,186

**INFORMATION DISCLOSURE
STATEMENT**

Applicant

Bennett et al.

Filing Date

July 30, 2001

Group

1635

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	6,165,788	12/26/2000	Ackermann et al.		

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Genbank Accession No. AW247335
C2	Grossman et al., "Expression of the Apoptosis Inhibitor, Survivin, in Nonmelanoma Skin Cancer and Gene Targeting in a Keratinocyte Cell Line," Laboratory Investigation, United States and Canadian Academy of Pathology, 29:1121-1126 (1999).
C3	Li et al., "Pleiotropic Cell-Division Defects and Apoptosis Induced by Interference with Survivin Function," Nature Cell Biology, 1:461-466 (1999).
C4	European Supplementary Search Report. European Application No. EP 01 90 8740.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.